or Try an Advanced Search...

    Technical Analysis for MLTX - MoonLake Immunotherapeutics

    Grade Last Price % Change Price Change
    C 41.80 -4.94% -2.17
    MLTX closed down 4.94 percent on Monday, July 1, 2024, on 1.42 times normal volume. It was able to find support at its 50 day moving average.
    2 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Up Up
    Historical MLTX trend table...
    Date Alert Name Type % Chg
    20 DMA Support Bullish 0.00%
    50 DMA Support Bullish 0.00%
    Wide Range Bar Range Expansion 0.00%
    Upper Bollinger Band Walk Strength 0.00%
    Upper Bollinger Band Touch Strength 0.00%
    20 DMA Support Bullish -4.94%
    50 DMA Support Bullish -4.94%
    MACD Bullish Signal Line Cross Bullish -4.94%
    Expansion Pivot Buy Setup Bullish Swing Setup -4.94%
    Up 3 Days in a Row Strength -4.94%
    Older End-of-Day Signals for MLTX ...

       Recent Intraday Alerts

    Alert Time
    50 DMA Support about 5 hours ago
    Fell Below 50 DMA about 5 hours ago
    Down 5% about 5 hours ago
    Down 1 ATR about 7 hours ago
    Down 3% about 8 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    MLTX Chart by TradingView
    Basic chart:

    Profile

    MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company unlocking the potential of sonelokimab, the first investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients. Sonelokimab optimally inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients. The Company’s focus is on inflammatory diseases with a major unmet need with lead indications currently progressing into Phase 2 trials for hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis or radiographic axial spondyloarthritis. MoonLake is headquartered in Zug, Switzerland.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Clinical Medicine Organ Systems Autoimmune Disease Inflammation Inflammatory Diseases Arthritis Rheumatology Psoriatic Arthritis Hidradenitis Suppurativa Interleukin 17 Interleukins Spondylitis

    Is MLTX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Jun 10 MoonLake Immunotherapeutics Announces Positive Regulatory Feedback from both FDA and EMA on Path for the Phase 3 Program for the Nanobody® sonelokimab in Psoriatic Arthritis
    May 16 MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
    May 12 MoonLake Immunotherapeutics' Competitive Edge In Autoimmune Market Expansion
    May 8 MoonLake Immunotherapeutics Reports Q1 2024 Financial Outcomes
    May 7 MoonLake Immunotherapeutics EPS of -$0.22 misses by $0.01
    May 7 MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
    Apr 10 MoonLake Immunotherapeutics Inks Three-Year Technology Partnership With Komodo Health To Advance Research on Inflammatory Skin and Joint Conditions
    Apr 2 Goldman starts MoonLake at neutral, cites lead drug potential
    Mar 11 MoonLake Jumps After Arthritis Drug Tops AbbVie Blockbuster Humira In A Key Test
    Mar 10 MoonLake announces significant improvements with Nanobody® sonelokimab over 24 weeks in active psoriatic arthritis (PsA) and other important updates at its R&D Day
    See more MLTX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 64.98
    52 Week Low 35.11
    Average Volume 333,013
    200-Day Moving Average 49.67
    50-Day Moving Average 41.47
    20-Day Moving Average 41.31
    10-Day Moving Average 40.36
    Average True Range 2.16
    RSI (14) 51.92
    ADX 15.67
    +DI 31.22
    -DI 15.63
    Chandelier Exit (Long, 3 ATRs) 39.28
    Chandelier Exit (Short, 3 ATRs) 44.03
    Upper Bollinger Bands 44.47
    Lower Bollinger Band 38.16
    Percent B (%b) 0.58
    BandWidth 15.27
    MACD Line -0.12
    MACD Signal Line -0.38
    MACD Histogram 0.259
    Fundamentals Value
    Market Cap 2.51 Billion
    Num Shares 59.9 Million
    EPS -1.06
    Price-to-Earnings (P/E) Ratio -39.43
    Price-to-Sales 0.00
    Price-to-Book 8.64
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 48.71
    Resistance 3 (R3) 49.27 47.51 47.56
    Resistance 2 (R2) 47.51 45.75 47.24 47.18
    Resistance 1 (R1) 44.66 44.66 43.78 44.10 46.79
    Pivot Point 42.90 42.90 42.47 42.63 42.90
    Support 1 (S1) 40.05 41.14 39.17 39.50 36.81
    Support 2 (S2) 38.29 40.05 38.02 36.42
    Support 3 (S3) 35.44 38.29 36.04
    Support 4 (S4) 34.89